Real-World Study of IL-23 Inhibitors in Active Crohn's Disease

计划入组 665 人 · 首次发布于 2026 年 4 月 22 日

Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease

计划入组 50 人 · 首次发布于 2026 年 3 月 4 日

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

计划入组 36 人 · 首次发布于 2024 年 5 月 3 日

IL-23 targeting double-bridged peptides (EPFL)

XmAb TL1A x IL-23 Program (Xencor)

anti-IL-23 therapeutic (gastroenterology)

Simcha Il 18, Inc.

United States

Alliance Foundation Trials, LLC

United States

Innate Pharma S.A.

FDA Approves Two IL-23 Inhibitors for Crohn's Disease as Gastroenterology Advances in 2025

IL-17 and IL-23 Inhibitors Show Promising Safety and Efficacy Profiles in Elderly Psoriasis Patients

IL-23 Inhibitors from J&J and Lilly Show Efficacy in Crohn's Disease Trials